Prof. Mark Kendall
CEO & Founder
(BE PhD FRSA FTSE FNAI):
Professor Mark Kendall is a biomedical engineer, inventor, scientist, entrepreneur and business-builder with more than 25 years’ experience in creating medical technologies to tackle key global health challenges.
Companies licensing/advancing his patents/technologies have created a combined economic value of more than $2 billion for investors.
Mark is the Founder and CEO of WearOptimo.
While at the University of Oxford, Mark was an inventor of the biolistics technology, commercialised with PowderJect (sold to Chiron Vaccines for US$1 Billion in 2003), and then PowderMed, purchased by Pfizer for US$400 million in 2006. Mark was then Founder, CTO and a Director of Vaxxas (2011-2015), which was the commercialisation vehicle for his Nanopatch vaccine delivery invention, featured in his TEDGlobal talk, which has >1 million views.
In recognition of his innovation and translation of commercial technologies focused on the delivery of drugs to skin, and skin-based disease diagnostics, Mark has received more than 40 awards and accolades.
These include the 2016 CSL Young Florey Medal, a 2012 Rolex Laureate Award for Enterprise and the Eureka Prize for Interdisciplinary Research (2011). He was also named a 2015 World Economic Forum Technology Pioneer,winner of The Australian Innovation Challenge in 2011 and 2004 Younger Engineer of Britain. Mark’s work has featured in diverse media outlets, including TEDGlobal, WIRED, ABC, BBC, NBC, National Geographic, New Scientist, Popular Science and Vanity Fair.
Mark’s international recognition extends to his election as a Fellow: of the National Academy of Inventors (NAI, USA); the Royal Society for the encouragement of Arts, Manufactures and Commerce, (RSA, UK); and Australian Academy of Technology and Engineering (ATSE).
With a strong global network, and a significant international profile, Mark serves on the World Economic Forum Global Future Council on Biotechnology and is co-chair of the Australian Stem Cell Therapies Mission.